Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


2011 Scrip 100: Novel drugs stage a comeback? Not exactly

This article was originally published in Scrip

Executive Summary

For Phase II to Phase III trials started between October 2009 and September 2010, Novartis led the charge by some distance, with 144 studies heavily concentrated in autoimmune/inflammation and oncology. In fact, Novartis is among the top five sponsor rankings in every therapeutic area we examined, taking first place in autoimmune/inflammation and cardiovascular; second place in oncology, CNS and infectious disease; and third in metabolic/endocrinology.

You may also be interested in...

Where in the world? Clinical trial activity reveals competitor strategies

The challenges of clinical development are well known, and ever increasing pressure to do more with less is not unique to this industry. Couple this pressure with lengthy development timelines and increasingly complex procedures and protocols, and development costs have soared over the past decade. Above all, trial recruitment remains the primary reason trials fail to complete on time and skyrocket beyond projected budgets.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts